Clinical trials: Immunocompromised Patients
Viral Infection, Hematopoietic Stem Cell Transplantation (HSCT)
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts
This is a Phase I dose-escalation study to evaluate the safety of norovirus -specific T-cell (NST) therapy for chronic norovirus infection in participants following hematopoietic stem cell transplantation (HSCT) or who are…
- Conditions
- Viral Infection, Hematopoietic Stem Cell Transplantation (HSCT), Primary Immunodeficiency Disorders (PID)
- Trial name
- ATLANTIC (NCT04691622)
- Testing
- Norovirus -specific T-cell (NST) therapy
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Children's National Research Institute
Candidiasis, Esophageal, HIV Infections
Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients
To determine the appropriate duration of amphotericin B therapy for Candida esophagitis. To compare the effectiveness of two different amphotericin B doses in the treatment of biopsy-proven Candida esophagitis.
- Trial name
- NCT00002041
- Testing
- Amphotericin B
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Anogenital Herpes, COVID-19
Viral Infections in Healthy and Immunocompromised Hosts
Background: Viral infections are an important cause of illness and death in hospitalized patients as well as outpatients. New strains of viruses may appear and infect both healthy people and those with weak immune systems.
- Conditions
- Anogenital Herpes, COVID-19, Herpes Labialis
- Trial name
- NCT01306084
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human
A Pilot Study of Influenza Viruses Isolated From Immunocompromised Children and Adolescents
The purpose of the proposed study is to gather critical information that may be useful in designing effective prevention and treatment strategies for control of seasonal influenza and an influenza pandemic.
- Trial name
- NCT02352389
- Testing
- Blood sample, Nasal swab, Oropharyngeal swab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- St. Jude Children's Research Hospital
Focus: Immunocompromised Individuals at High Risk of Aqcuiring Invasive Aspergillosis
Diagnostic Performance of an Aspergillus-specific Nested PCR Assay in Cerebrospinal Fluid Samples
Multicentre, diagnostic study evaluating the performance of an aspergillus-specific PCR in cerebrospinal fluid samples of immunocompromised patients for identification of central nervous system aspergillosis.
- Trial name
- NCT01614145
- Where
- 3 sites in Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Heidelberg University
BK Polyomavirus
Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients
This is a pilot study using cytotoxic T lymphocytes (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Gamma-capture system will be effective in decreasing specific viral load in patients with BK virus viremia and BK…
- Trial name
- BK-CTLs (NCT04293042)
- Testing
- BK-virus specific CTLs
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital of Philadelphia
Hematopoietic and Lymphoid Cell Neoplasm, Influenza
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
This phase II trial studies the effect of baloxavir in combination with oseltamivir in treating severe influenza infection in patients who have previously received a hematopoietic (blood) stem cell transplant or have a…
- Trial name
- NCT04712539
- Testing
- Baloxavir Marboxil, Oseltamivir
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Aspergillosis
To Determine Whether Galactomannan Test Will Help to Detect Fungal Infections Early and Hence Start Treatment Early
Chemotherapy lowers the white blood cell count or weakens the immune system for a long time. This puts the patients at a high risk of getting a serious fungal infection of the internal organs or blood.
- Trial name
- NCT00361517
- Testing
- Galactomannan antigen monitoring, Aspergillus PCR, blood draws, blood draws for GM monitoring
- Where
- Singapore
- Volunteers
- 47 people
- Sponsor
- Singapore General Hospital
RSV Infection
Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children
Study D5290C00008 is a Phase 2, open-label, uncontrolled, single-dose study to evaluate the safety and tolerability, pharmacokinetic(s) (PK), occurrence of antidrug antibody (ADA), and efficacy of nirsevimab in immunocompromised…
- Trial name
- MUSIC (NCT04484935)
- Testing
- Nirsevimab
- Where
- 28 sites in United States, Belgium and 6 more
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Hematologic Disease, Neoplams
Retrospective Non-interventional Analysis of Opportunistic Infections in Immunocompromised and Frail Patients
The analysis of a cohort of consecutive non-selected patients from the Strasbourg University Hospital, and therefore representative of the real life, will allow better identifying the risk factors for these infections (by…
- Conditions
- Hematologic Disease, Neoplams, Transplantation, Immunologic Deficiency Syndromes
- Trial name
- NCT03920735
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Strasbourg, France
Immune Response to Covid 19 Vaccination
Comparative Study of Patterns of Immune Response to COVID 19 Vaccination
An effective vaccine stands as the most effective way for controlling the COVID 19 pandemic , yet, immunogenic vaccine efficacy needs to be extensively studied .
- Trial name
- NCT05408299
- Testing
- Covid vaccines (Moderna - Pfizer- Astra Zeneca- Johnson and Johnson - Sinopahrm)
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- National Research Centre, Egypt
Shingles, Bone Marrow Transplantation
Valacyclovir in Immunocompromised Children
Shingles is an infection commonly seen in children with a weakened immune system (immunocompromised children). The immune system can be weakened as a result of medications that patients receive for cancer or other serious illness…
- Trial name
- NCT00059592
- Testing
- Valacyclovir
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Baylor College of Medicine
Cytomegalovirus Retinitis, HIV Infections
An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children
To evaluate the pharmacokinetics of intravenous ganciclovir in children (ages 3 months - 12 years). To determine the safety and tolerance of a 2 to 3 week induction course of ganciclovir IV in immunocompromised children receiving…
- Trial name
- NCT00002015
- Testing
- Ganciclovir
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Roche Global Development
Immuno-Deficiency, COVID-19
PREP (Pre-Exposure Prophylaxis) of COVID-19
This is a study of immunocompromised individuals who have received or plan to receive a drug called EVUSHELD. This study is looking at any serious adverse events that might happen after receiving EVUSHELD, the levels of EVUSHELD…
- Trial name
- PrEP (NCT05461378)
- Testing
- Evusheld
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Ghady Haidar
Neutropenia
A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients With Persistent Fever and Neutropenia
The purpose of this study is to evaluate the safety and effectiveness of 2 drugs (AmBisome versus voriconazole) in treating fungal infections.
- Trial name
- NCT00008840
- Where
- United States
- Volunteers
- 866 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2, COVID-19
eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and…
- Trial name
- VALOR C19 IL (NCT05712096)
- Testing
- EVUSHELD
- Where
- Israel
- Volunteers
- 4,000 people
- Sponsor
- AstraZeneca
Meningococcal Disease
Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.
The study aims at evaluating the safety and immunogenicity of rMenB+OMV NZ when administered to subjects from 2 to 17 years of age with increased risk of meningococcal disease because either of primary or secondary complement…
- Trial name
- NCT02141516
- Testing
- rMenB+OMV
- Where
- 20 sites in Italy, Poland and 3 more
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Novartis
Adenovirus, Cytomegalovirus Infections
Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV
The primary purpose of this phase I/II study is to evaluate whether partially matched, ≥2/6 HLA-matched, viral specific T cells have efficacy against adenovirus, CMV or EBV in subjects who have previously received any type of…
- Conditions
- Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus
- Trial name
- NCT04364178
- Testing
- Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, EBV Specific T-Lymphocytes
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jessie L. Alexander, MD
Respiratory Syncytial Virus Infection
Prevention of RSV Infections in Bone Marrow Transplant Recipients
Respiratory Syncytial Virus (RSV) infections are very common and widespread. By age 5, virtually everyone has been infected and developed antibodies against some strain of the virus.
- Trial name
- NCT00001903
- Testing
- RSV Polyclonal Immunoglobulin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immunocompromised Patients, Safety of Pandemic Influenza A (H1N1)Vaccine
Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants
The objective of this study is to describe the safety and immunogenicity of a non-adjuvanted vaccine against pandemic influenza A (H1N1)in patients with chronic and or immunocompromised disease, elderly and pregnants.
- Conditions
- Immunocompromised Patients, Safety of Pandemic Influenza A (H1N1)Vaccine, Immunogenicity of Pandemic Influenza A (H1N1)Vaccine
- Trial name
- NCT01218685
- Testing
- Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS
- Where
- Brazil
- Volunteers
- 1,152 people, healthy volunteers welcome
- Sponsor
- Butantan Institute